Pure Global AI
NCT06146946Not yet recruiting

Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)

Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node, a Prospective, Multicenter, Non-inferior Randomized Controlled Trial
Cancer Institute and Hospital, Chinese Academy of Medical SciencesClinicalTrials.govprocedure
Verified
Study focus
Disease/Condition
Rectal Cancer
Drug/Device/Intervention
Dissection of the No.253 lymph node
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Location
Beijing,Beijing,Beijing,Beijing,Shanghai,Shanghai,Chengdu, China
Timeline & enrollment
Phase
N/A
Start date
Dec 01, 2023
End date
Dec 01, 2029
Enrollment
1384 participants
Primary outcome

3-year disease free survival rate

Summary

The goal of this clinical trial is to learn about whether it is safe to omit dissection of
 the No.253 lymph nodes in mid and low rectal cancer surgery. The main question it aims to
 answer is that if it is possible to achieve the same long-term survival with and without the
 dissection of the No.253 lymph node in mid and low rectal cancer surgery. Participants will
 underwent laparoscopic rectal radical resection with or without the dissection of the No.253
 lymph node.

ICD-10 classifications
Malignant neoplasm of rectumCarcinoma in situ: RectumBenign neoplasm: RectumSecondary malignant neoplasm of large intestine and rectumCarcinoma in situ: Rectosigmoid junction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06146946
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06146946 through Pure Global AI's free database. This phase not specified trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Not yet recruiting. The study focuses on Rectal Cancer. Target enrollment is 1384 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.